200 molecular weight, 27 mg of microcrystalline cellulose having a 0.09 mm particle size and a 36,000 molecular weight, 36 mg of polyvinylpyrrolidone having a 35,000 molecular weight, and 5 mg of magnesium stearate, are dry blended for 17 to 20 minutes in a blender to produce a homogenous...
FIG. 2 illustrates a driving member system 36 utilizing an expandable driving member 38 comprised of an external fluid insoluble, external fluid swellable composition. Member 38 is encased in housing 40 which is a semipermeable membrane substantially permeable to the passage of an external fluid and ...
D is the diffusivity through the material in path34or36in cm2/day r is the effective inner radius of the flow path in cm ΔCais the difference between the concentration of agent A in the reservoir and in the body outside of the outlet22in mg/cm3 ...
the length of sleeve 30 coincides with the end of rear end 8 when rear end 8 has undergone the expansion that often occurs as a result of fluid imbibition. The protective sleeve 30 may optionally be radiused or contoured to form a lip 36, as illustrated in FIG. 4, to partially cover ...
(i.e., on the skin side) thereof. Lower adhesive region 36 provides the means by which lower housing 20 may be folded back upon, and adhered to, itself, thereby retaining drug reservoirs 26, 28 (and electrodes 22, 24) therein. (A folded lower housing 20 is better shown in FIG. 4 ...
Intrauterine device 10 can have different shapes and dimensions, and these can vary consistent with comfortable placement and effective drug release, in uterus 36. In one application, device 10 is useful for releasing an active agent to the uterus by controlled bioerosion in situ. Device 10 can ...
such combinations may have the added therapeutic effect of both agents but less side effects, or the drugs may act synergistically and create a larger than additive effect. Also, drug combinations are prescribed for treatments where each individual drug address different symptoms of a particular medic...
A still further object of the invention is to provide a delivery system that avoids patient compliance problems and uses less drug, minimizes side effects and thereby provides efficiency in treatment for better health. Other objects, features, aspects and advantages of the invention will be more ...
Sadzuka, Y., et al., “Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11” Cancer Letters 127:99-106 (1998). Zhu, G., et al., “The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tum...
the active agent formulation is present as a plurality of active agent dosage forms as layers or tablets 36, 38, 40 and 42. Although four dosage forms are illustrated, the number is not critical and any number of dosage forms are included under the invention. Optionally, layers of a barrier...